
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Research Articles |
Authors' Affiliations: 1 Division of Human Biology, Fred Hutchinson Cancer Research Center; 2 Department of Environmental and Occupational Health, University of Washington, Seattle, Washington; and 3 Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey
Requests for reprints: Helmut Zarbl, Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, EOHSI, 170 Freylinghuysen Road, Room 426, Piscataway, NJ, 08854. Phone: 732-445-2354; E-mail: zarbl{at}eohsi.rutgers.edu.
| Abstract |
|---|
|
|
|---|
Key Words: selenium chemoprevention mammary carcinogenesis microarray circadian
|
|
|---|
The mechanisms of selenium-mediated chemoprevention in vivo are still poorly understood at the molecular level. Early hypotheses focused on selenoproteins such as glutathione peroxidase, an enzyme involved in reducing reactive oxygen species [reviewed by Ganther (9)]. However, because maximum glutathione peroxidase enzyme activity is attained in animal tissues without selenium supplementation, it is improbable that the latter mechanism plays a significant role (10–14). More recent studies reviewed by Whanger (15) have focused on the ability of methylselenocysteine to suppress cell proliferation and induce apoptosis in vitro and in vivo. Nonetheless, the exact pathways involved in these processes in vivo are still unclear, and alternative mechanisms of chemoprevention have not been ruled out.
In an attempt to further define the molecular bases for selenium chemoprevention, several studies used DNA microarray technology to compare selenium-induced changes in gene expression profiles in different types of mammary samples including whole mammary gland, premalignant tumor cell lines, and mammary tumors or in vivo system (for review, see ref. 16). The results of these studies showed that chemopreventive selenium altered the steady-state levels of a wide spectrum of genes that are involved in cell cycle, tumor growth inhibition, metabolism, and apoptosis. Moreover, many of the selenium-mediated changes in gene expression were dependent on the experimental system, suggesting that selenium probably exerted its chemopreventive effects via multiple mechanisms. In the present study, we first investigated the chemopreventive potential of methylselenocysteine in the Fischer 344 (F344) rat. Our results showed that, as in other strains, dietary supplementation with selenium (3 ppm) in the form of methylselenocysteine for 30 days following N-nitroso-N-methylurea (NMU) exposure reduced the incidence of mammary carcinogenesis by
60% in the F344 strain. Consistent with the results of previous studies, we found that the chemopreventive levels of methylselenocysteine regulated the expression of genes involved in numerous cellular processes. However, unlike previous studies, our results showed that during the course of selenium-induced chemoprevention, there were significant effects on both the steady-state levels and temporal oscillations of genes involved in circadian rhythm in mammary tissue. Moreover, the selenium-induced increases in circadian genes were suppressed in all tumors that arose in all NMU-treated animals maintained on the selenium-enriched diet.
| Materials and Methods |
|---|
|
|
|---|
Chemoprevention study
To induce mammary tumors, 60 female F344 rats, between the ages of 50 and 55 d, were injected i.p. with a single 50 mg/kg body weight dose of NMU (Ash Stevens, Inc.). NMU was dissolved in acidified saline at a final concentration of 10 mg/mL just before injection. After chemical treatment, animals were randomly divided into two groups and maintained on either the basal AIN-76A diet or the selenium-supplemented diet (3 ppm selenium) until the termination of the experiment. All animals were examined weekly to determine the appearance, size, and location of mammary tumors. All rats were euthanized by CO2 32 wk after carcinogen administration. At necropsy, the mammary gland was carefully examined for the palpable and nonpalpable mammary tumors. All tumors as well as normal mammary gland were excised and fixed in normal buffered formalin for later histopathologic diagnosis. Only confirmed adenocarcinomas were included in the data analysis. Tumor incidences of two dietary regimens at the final time point were compared by
2 analysis, and the inhibition of tumorigenesis was calculated based on the total tumor yields from both groups.
RNA isolation
For microarray experiments, total RNA was isolated from mammary glands on the left side of each animal with Qiagen RNeasy Maxi Kit following the manufacturer's protocol. The isolated RNA was then precipitated twice with 4 mol/L LiCl, resuspended in 3 mol/L sodium acetate (pH 5.2), and precipitated from ethanol, followed by two washes with 80% ethanol. Alternatively, total RNA from mammary gland was isolated with Trizol (Invitrogen) and purified on Qiagen RNeasy Mini Kit. Liver total RNA was isolated with Qiagen RNeasy Mini Kit. Purified RNA was resuspended in RNase-free water (Sigma) and stored at –80°C.
Microarray analysis
Gene expression profiles of mammary tissue were determined using Affymetrix GeneChip oligoarray (Affymetrix) at Icoria, Inc. (former Paradigm Genetics). Biotinylated cRNA samples were prepared according to the standard Affymetrix GeneChip protocol (Affymetrix). In brief, 1 µg of total RNA from each sample added to poly(A) as a labeling control was converted to double-stranded cDNA with GeneChip One-Cycle cDNA Synthesis Kit. After second-strand synthesis, the cDNA is purified with the GeneChip Sample Cleanup Module. The resulting double-stranded DNA is then used to generate multiple copies of biotinylated cRNA by in vitro transcription with the GeneChip 3'-Amplification Reagent Kit for IVT Labeling. The amount and quality of the fluorescently labeled cRNA were assessed with a Nanodrop ND-100 spectrophometer and an Agilent Bioanalyzer. For each sample, 15 µg of biotinylated cRNA added to bioB, bioC, bioD, and cre (microarray hybridization controls) were hybridized to a GeneChip Rat Genome 230 2.0 Array (Affymetrix) for 16 h at 45°C. Following hybridization, all arrays were washed and stained in an Affymetrix GeneChip Fluidics Station. Stained arrays were scanned with an Affymetrix GeneChip Scanner 3000. Quality check (visual inspection of image, percent Present calls, background, scaling factor, 3'/5' glyceraldehyde-3-phosphate dehydrogenase and β-actin ratios, detection call of biotin spike-in) and data analysis were carried out using Affymetrix GeneChip Operating Software and Quality Reporter.
Statistical analysis
To identify the differentially expressed genes between control diet and selenium-supplemented diet, data from the selenium samples and control samples were combined using an error-weighted average using Rosetta Resolver version 5.1.0.1.0 (Rosetta Biosoftware). The combined data were compared to create a ratio in which the selenium samples were in the numerator and the control samples were in the denominator. Transcripts showing an absolute fold change >1.3, a log ratio P < 0.001, and a combined log10 intensity of >–1 were considered significant.
Gene enrichment analysis
Genes that were differentially expressed between control and selenium diets were imported into GoMiner,4 a gene ontology enrichment tool for identifying gene symbols. Transcripts with no associated gene symbol were omitted from these analyses as they have not been attributed by the Gene Ontology (GO) consortium to a biological process. The input list was used as a means to identify the enrichment of biological processes using High-Throughput GoMiner (17).
Quantitative real-time PCR
To validate the data obtained from microarrays, a fluorogenic 5' nuclease–based real-time PCR assay was used to quantitate the mRNA levels of specific genes in the same samples analyzed on microarrays. Briefly, reverse transcription was done according to the manufacturer's established protocol using 1 µg of total RNA and iScript cDNA Synthesis Kit (Bio-Rad Laboratories). For gene expression measurements, 4 µL of cDNA were included in a PCR reaction (16-µL final volume) that included the appropriate forward and reverse primers at 438 nmol/L each, 188 nmol/L TaqMan probe, and 1x TaqMan Fast Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, Inc.). The PCR primers and the dual-labeled probes [6-carboxy-fluorescein (FAM) and 6-carboxy-tetramethyl-rhodamine (TAMRA)] used were listed in Supplementary Table S1. β-Actin gene expression levels were used as an internal control to normalize the data for all individual genes.
| Results |
|---|
|
|
|---|
50% to 70% in tumor incidence. As shown in Fig. 1, at 24 weeks, we also observed a dramatic reduction in the incidence of mammary carcinomas in F344 female rats maintained on the enriched selenium diet. For rats on the control diet, the first mammary tumor appeared
10 weeks after NMU administration, whereas on the selenium diet no tumors were detected until 23 weeks after NMU exposure.
|
|
Global gene expression profiles of mammary gland at day 30 after NMU exposure
To identify the genes and pathways that are affected during chemoprevention, we generated global gene expression profiles of rat mammary cells in the presence and absence of methylselenocysteine supplementation. Seventy-two, 50-day-old female F344 rats were randomly divided into two groups receiving an i.p. injection of either NMU (50 mg/kg body weight) or the vehicle. Rats under each treatment were further divided into two groups: those fed the standard AIN-76A diet and those fed the AIN-76A diet supplemented with methylselenocysteine (3 ppm selenium). Six rats from each group were sacrificed on days 1, 7, and 30 after chemical treatment. Mammary glands were harvested and quickly transferred into RNAlater to preserve the integrity of RNA. To minimize the variation between animals, total RNA was isolated from mammary glands from the left side of all individual rats.
Previous studies showed that the chemoprevention by organic selenium required that animals be fed the enriched diet for a period of 1 month, after which incidence of mammary tumor in rats was essentially the same as that of rats fed on chemopreventive selenium diet for 6 months (7). This observation suggests that the crucial selenium-induced effects on mammary gland occur during the first month after chemical exposure. Therefore, we first compared gene expression profiles of total RNA samples from the NMU-treated group at day 30 after exposure. Using the Affymetrix Rat Genome 230 2.0 oligoarray, which analyzes more than 30,000 transcripts and variants from more than 28,000 well-substantiated rat genes, we generated profiles of whole mammary gland from rats on control diet (n = 6) and selenium diet (n = 6). Expression profiles were then analyzed for differentially expressed genes using several analytic software packages, including Rosetta Resolver, TIGR MultiExperiment Viewer (The Institute for Genomic Research), and ArrayAssist software (Stratagene). The results obtained with all of these analysis tools were similar (data not shown) and identified 79 transcripts that were differentially expressed between control diet and selenium diet using the following criteria: ratio P < 0.001, absolute fold change >1.3, and combined log10 intensity >–1. Among these differentially expressed transcripts, 54 transcripts were up-regulated and 25 transcripts were down-regulated by the selenium-enriched diet. These genes are involved in various biological processes such as metabolism, cell proliferation, and signal transduction. Data from the 40 differentially expressed genes with good annotation were further evaluated for gene ontology using GoMiner. The gene enrichment analysis (Table 2) showed that several clock genes involved in circadian rhythm, including Per2, Per3, DBP, Cry2, and Arntl (Bmal1), were among the set of genes that showed the greatest response to dietary selenium supplementation.
|
|
|
|
| Discussion |
|---|
|
|
|---|
Gene expression profiling of mammary glands identifies circadian genes as novel targets of selenium
Previous studies have suggested that selenium might exert its chemopreventive effects at the early stage of mammary carcinogenesis (5–7). We hypothesized that by studying the differences in gene expression profiles of mammary cells with NMU exposure in the presence and absence of supplemental dietary selenium, we could identify key regulatory elements modulated by selenium that are essential to the promotion of mammary carcinogenesis. In designing these studies, we first had to decide what cells to use for expression profiling. Although rat mammary carcinomas are considered to originate from ductal epithelium, the importance of the interaction between epithelial cells and stromal cells has been widely acknowledged (28–30). In addition, the percentage of mammary epithelial cells dramatically decreases as mammary gland develops past puberty, making it difficult to isolate and enrich the epithelial cell population. Moreover, techniques used for isolating mammary epithelial cells, such as laser capture microdissection or cell-surface marker–based cell sorting, entail the risk of altering the in vivo gene expression patterns in the mammary cells. For these reasons, we chose to focus our analyses on expression profiles in whole mammary tissue rather than isolated mammary epithelial cells.
Several previous studies examining the chemopreventive effects of selenium using either cDNA or oligonucleotide arrays (19, 31–33) implicated genes involved in multiple biological processes, including cell cycle regulation (e.g., CDK1, CHK2, and cyclin A), apoptosis (e.g., bcl-2 and bax), and signal transduction. However, all these previous data were derived from cancer cell lines or mammary tumors, and therefore may not have detected selenium-induced changes in gene expression at the early stage of carcinogenesis, which are essential to chemoprevention. We therefore examined the effects of selenium on the entire genome in the whole mammary gland at various times early in the process of NMU-induced carcinogenesis. Using a relatively stringent P value combined with signal intensity and fold change, we identified a number of differentially expressed genes that were associated with organic selenium supplementation. The genes and biochemical pathways involved in regulating circadian rhythm were among the most significantly and consistently altered by the selenium-enriched diet. Our observation that Per2 expression is reduced in tumors relative to adjacent normal mammary confirms the possibility that important selenium-modulated genes are selected against during the process of carcinogenesis.
Circadian genes are implicated in tumorigenesis
The circadian gene family consists of eight core members: Clock, casein kinase I
(CKI
), cryptochrome 1, 2 (Cry1, Cry2), Period 1, 2, 3 (Per1, Per2, Per3), and Bmal1. The circadian clock sustains rhythms of
24 hours in the absence of external cues via feedback loops of the circadian genes in the suprachiasmatic nuclei, as well as in most peripheral tissues (34).
Because circadian clock genes play a role in normal development and differentiation of mouse mammary gland (35), the disruption of circadian genes has led to the speculation of its involvement in mammary tumorigenesis. The possibility that disruption of circadian rhythm in women led to increased mammary tumor development was first reported in the 1960s, and ongoing studies showed that disruption of circadian endocrine rhythm accelerates breast epithelial stem-cell proliferation, induces mammary gland development, and increases the formation of spontaneous mammary tumors in rodents (34). A breakthrough in the study of circadian rhythm and its connection with cancer development came when Per2, a core circadian gene, was shown to have tumor suppressor activity. Lee and colleagues showed that mice deficient in the Per2 gene not only lost circadian rhythm (36) but were also cancer prone (21, 37). Given the role of Per2 in tumor suppression, we speculated that selenium may exert its chemopreventive effects by up-regulating Per2, which may subsequently regulate DNA-damage responses, cell proliferation, and apoptosis, thus acting as a tumor suppressor. Our hypothesis is supported by our observation that the up-regulation of Per2 was consistently abolished in mammary carcinomas that arose in NMU-treated rats on the organic selenium-enriched diet, whereas Per2 gene expression levels were unaffected in adjacent normal tissues. These findings suggested biological selection against elevated Per2 during the process of carcinogenesis in this setting. Moreover, at least two other studies have reported abnormal expression of Per1, Per2, and Per3 in endometrial carcinomas and human breast cancer tissues (38, 39). A more recent study showed that Per2 binds to the estrogen receptor
, and that binding enhances degradation of the estrogen receptor-
protein (40). Because estrogen is a promoter of mammary carcinogenesis in cells expressing estrogen receptor
, increased levels of Per2 provide a mechanistic link between a selenium-enriched diet and inhibition of mammary carcinogenesis at the postinitiation stage. This hypothesis is further supported by our recent preliminary data suggesting that the selenium-enriched diet also induces periodic expression of estrogen receptor genes in mammary tissue (data not shown).
If circadian gene expression were regulated by organic selenium, then the question is, how does selenium modulate the level of these genes? Our initial studies only compared steady-state levels of genes in mammary tissue during a narrow window within 24 hours. To gain a better insight into how dietary selenium affected the regulation on circadian genes, we monitored the expression levels of Per2 and DBP every 4 hours over a 24-hour period. Liver cells showed that the anticipated circadian regulation and selenium did not have any effect on the level of Per2 and DBP gene expression. By contrast, Per2 levels in mammary glands from animals on the control diet failed to show the expected circadian oscillation over the 24-hour period. Unlike liver, of which the major functions are metabolism and detoxification, the mammary gland is highly sensitive to hormonal regulation. Because the autonomic nervous system and the neuroendocrine system are regulated by the suprachiasmatic clock, maintaining a steady level of Per2 in normal mammary gland may have its significance in balancing the hormonal input and output signals essential for normal function of the organ. A similar observation was made in mouse where eight circadian genes, including Per2, showed robust circadian expressions of mRNA in all peripheral tissues examined (heart, lung, liver, stomach, spleen, and kidney) except testis (41).
Unexpectedly, our analysis showed that circadian oscillation over 24 hours was dramatically up-regulated in mammary glands by dietary selenium supplementation, beginning a few hours following the light to dark transition. DBP, an output gene of the circadian clock, showed a similar expression profile to that of Per2, suggesting that selenium also affects the circadian output signals. Several epidemiologic studies have shown that the disruption of circadian cycles, particularly among people working predominantly at night, leads to an increased risk of developing breast cancer (42–44). The proposed mechanism for the observed effects of circadian disruption on mammary carcinogenesis is that exposure to light at night rapidly suppresses melatonin production, which is a rhythmic neuronal activity regulated by suprachiasmatic nuclei (45). Therefore, comparisons of serum melatonin levels between animals on the control and the selenium-enriched diets should help establish a putative link between Per2 and melatonin in the future.
Although previous studies reported that circadian gene expression can be induced by serum shock or down-regulated by glucose in cultured Rat-1 fibroblasts (46, 47), we are the first to show that the dietary supplement selenium can regulate circadian gene expression in mammary tissue in vivo. This finding was unexpected but not biologically implausible. Interestingly, recent studies have shown that transcription feedback loops of circadian genes can also be regulated by intracellular redox pathways. Reduced forms of the redox cofactors, NAD(H) and NADP(H), strongly enhance DNA binding of the Clock:Bmal1 and NPAS2:Bmal1 heterodimeric transcription factors that regulate circadian gene expression, whereas oxidized forms inhibit DNA binding (48). The targets that the Clock:Bmal1 complex regulates include Per and Cry genes (34). As an antioxidant, selenium-mediated redox reactions involve the cycling of reduced glutathione and oxidized glutathione, which is coupled by NADP/NADPH. The latter may further regulate circadian gene expression.
In summary, the present study showed that dietary selenium in the form of methylselenocysteine inhibits NMU-induced mammary carcinogenesis in female F344 rats with the same efficacy as in Sprague-Dawley rats. By combining in vivo chemoprevention studies with genomic microarray analysis of the target tissue, we identified clock genes as novel targets of selenium chemoprevention during the early stage of mammary carcinogenesis. Given previous observations that circadian gene Per2 is a tumor suppressor (21) and accumulating epidemiologic evidence that disruption of normal circadian rhythm may increase the risk of cancer development (43, 44, 49), our study provides a new insight into the mechanism of selenium-induced chemoprevention.
| Disclosure of Potential Conflicts of Interest |
|---|
|
|
|---|
| Acknowledgments |
|---|
|
|
|---|
| Footnotes |
|---|
Note: Supplementary data for this article are available at Cancer Prevention Research Online (http://cancerprevres.aacrjournals.org/).
Current address for X. Zhang: Department of Genetics and Genomics, Roche Palo Alto, S3-1, 3431 Hillview Avenue, Palo Alto, CA 94304.
4http://discover.nci.nih.gov/gominer ![]()
Received for publication February 20, 2008.
Accepted March 10, 2008
| References |
|---|
|
|
|---|
2. Ip C Lisk DJEfficacy of cancer prevention by high-selenium garlic is primarily dependent on the action of selenium. Carcinogenesis 1995;16:2649–52.
3. Ip C, Zhu Z, Thompson HJ, Lisk D, Ganther HEChemoprevention of mammary cancer with Se-allylselenocysteine and other selenoamino acids in the rat. Anticancer Res 1999;19:2875–80.[Medline]
4. Ip C, Thompson HJ, Zhu Z, Ganther HEIn vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882–6.
5. Ip C Dong YMethylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland. Anticancer Res 2001;21:863–7.[Medline]
6. Ip CProphylaxis of mammary neoplasia by selenium supplementation in the initiation and promotion phases of chemical carcinogenesis. Cancer Res 1981;41:4386–90.
7. Lu J, Pei H, Ip C, Lisk DJ, Ganther H, Thompson HJEffect on an aqueous extract of selenium-enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. Carcinogenesis 1996;17:1903–7.
8. Ip C Ganther HEActivity of methylated forms of selenium in cancer prevention. Cancer Res 1990;50:1206–11.
9. Ganther HESelenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999;20:1657–66.
10. Ip C Lisk DJModulation of phase I, phase II. Xenobiotic-metabolizing enzymes by selenium-enriched garlic in rats. Nutr Cancer 1997;28:184–8.[Medline]
11. Ip C, Lisk DJ, Ganther HEChemoprevention with triphenylselenonium chloride in selenium-deficient rats. Anticancer Res 2000;20:4179–82.[Medline]
12. Yang JG, Hill KE, Burk RFDietary selenium intake controls rat plasma selenoprotein P concentration. J Nutr 1989;119:1010–2.
13. Lane HW, Tracey CK, Medina DGrowth, reproduction rates and mammary gland selenium concentration and glutathione-peroxidase activity of BALB/c female mice fed two dietary levels of selenium. J Nutr 1984;114:323–31.
14. Medina D, Lane HW, Shepherd FEffect of dietary selenium levels on 7,12-dimethylbenzanthracene-induced mouse mammary tumorigenesis. Carcinogenesis 1983;4:1159–63.
15. Whanger PDSelenium and its relationship to cancer: an update. Br J Nutr 2004;91:11–28.[CrossRef][Medline]
16. El-Bayoumy K Sinha RMolecular chemoprevention by selenium: a genomic approach. Mutat Res 2005;591:224–36.[Medline]
17. Zeeberg BR, Qin H, Narasimhan S et al High-Throughput GoMiner, an "industrial-strength" integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics 2005;6:168.[CrossRef][Medline]
18. Ip C, Lisk DJ, Thompson HJSelenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis 1996;17:1979–82.
19. Dong Y, Lisk D, Block E, Ip CCharacterization of the biological activity of
-glutamyl-Se-methylselenocysteine: a novel, naturally occurring anticancer agent from garlic. Cancer Res 2001;61:2923–8.
20. Ip C, Birringer M, Block E et al Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J Agric Food Chem 2000;48:4452.[Medline]
21. Fu L, Pelicano H, Liu J, Huang P, Lee CThe circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41–50.[CrossRef][Medline]
22. Rosbash M Takahashi JSCircadian rhythms: the cancer connection. Nature 2002;420:373–4.[CrossRef][Medline]
23. Holzberg D Albrecht UThe circadian clock: a manager of biochemical processes within the organism. J Neuroendocrinol 2003;15:339–43.[CrossRef][Medline]
24. Cha RS, Thilly WG, Zarbl HN-Nitroso-N-methylurea-induced rat mammary tumors arise from cells with preexisting oncogenic Hras1 gene mutations. Proc Natl Acad Sci U S A 1994;91:3749–53.
25. Jin Z, Houle B, Mikheev AM, Cha RS, Zarbl HAlterations in H-ras1 promoter conformation during N-nitroso-N-methylurea-induced mammary carcinogenesis and pregnancy. Cancer Res 1996;56:4927–35.
26. Cha RS, Guerra L, Thilly WG, Zarbl HHa-ras-1 oncogene mutations in mammary epithelial cells do not contribute to initiation of spontaneous mammary tumorigenesis in rats. Carcinogenesis 1996;17:2519–24.
27. Mikheev AM, Inoue A, Jing L et al Frequent activation of CArG binding factor-A expression and binding in N-methyl-N-nitrosourea-induced rat mammary carcinomas. Breast Cancer Res Treat 2004;88:95–102.[CrossRef][Medline]
28. Nandi S, Guzman RC, Yang JHormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A 1995;92:3650–7.
29. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein CThe stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004;117:1495–502.
30. Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi S, Medina DHormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res 2007;9:R12.[CrossRef][Medline]
31. Dong Y, Ganther HE, Stewart C, Ip CIdentification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res 2002;62:708–14.
32. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip CDelineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003;63:52–9.
33. Unni E, Kittrell FS, Singh U, Sinha ROsteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res 2004;6:R586–92.[CrossRef][Medline]
34. Fu L Lee CCThe circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 2003;3:350–61.[CrossRef][Medline]
35. Metz RP, Qu X, Laffin B, Earnest D, Porter WWCircadian clock and cell cycle gene expression in mouse mammary epithelial cells and in the developing mouse mammary gland. Dev Dyn 2006;235:263–71.[CrossRef][Medline]
36. Zheng B, Larkin DW, Albrecht U et al The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature 1999;400:169–73.[CrossRef][Medline]
37. Lee CCTumor suppression by the mammalian Period genes. Cancer Causes Control 2006;17:525–30.[CrossRef][Medline]
38. Yeh KT, Yang MY, Liu TC et al Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol 2005;206:111–20.[CrossRef][Medline]
39. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JGDeregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005;26:1241–6.
40. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HPThe clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007;26:7916–20.[CrossRef][Medline]
41. Yamamoto T, Nakahata Y, Soma H, Akashi M, Mamine T, Takumi TTranscriptional oscillation of canonical clock genes in mouse peripheral tissues. BMC Mol Biol 2004;5:18.[CrossRef][Medline]
42. Schernhammer ES, Laden F, Speizer FE et al Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001;93:1563–8.
43. Hansen JRisk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control 2006;17:531–7.[CrossRef][Medline]
44. Davis S Mirick DKCircadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control 2006;17:539–45.[CrossRef][Medline]
45. Blask DE, Dauchy RT, Sauer LA, Krause JAMelatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 2004;25:951–60.
46. Balsalobre A, Damiola F, Schibler UA serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 1998;93:929–37.[CrossRef][Medline]
47. Hirota T, Okano T, Kokame K, Shirotani-Ikejima H, Miyata T, Fukada YGlucose down-regulates Per1 and Per2 mRNA levels and induces circadian gene expression in cultured Rat-1 fibroblasts. J Biol Chem 2002;277:44244–51.
48. Rutter J, Reick M, Wu LC, McKnight SLRegulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 2001;293:510–4.
49. O'Leary ES, Schoenfeld ER, Stevens RG et al Shift work, light at night, and breast cancer on Long Island, New York. Am J Epidemiol 2006;164:358–66.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |